nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—PTGS2—urinary bladder cancer	0.518	1	CbGaD
Clodronate—PTGS2—Cisplatin—urinary bladder cancer	0.0491	0.505	CbGbCtD
Clodronate—PTGS2—Etoposide—urinary bladder cancer	0.0482	0.496	CbGbCtD
Clodronate—SLC25A6—prostate gland—urinary bladder cancer	0.0103	0.0836	CbGeAlD
Clodronate—SLC25A5—prostate gland—urinary bladder cancer	0.00892	0.0727	CbGeAlD
Clodronate—SLC25A4—prostate gland—urinary bladder cancer	0.00836	0.0682	CbGeAlD
Clodronate—SLC25A5—seminal vesicle—urinary bladder cancer	0.00754	0.0615	CbGeAlD
Clodronate—SLC25A6—epithelium—urinary bladder cancer	0.00753	0.0614	CbGeAlD
Clodronate—SLC25A6—renal system—urinary bladder cancer	0.00699	0.057	CbGeAlD
Clodronate—SLC25A5—epithelium—urinary bladder cancer	0.00655	0.0534	CbGeAlD
Clodronate—SLC25A5—smooth muscle tissue—urinary bladder cancer	0.00631	0.0515	CbGeAlD
Clodronate—SLC25A5—renal system—urinary bladder cancer	0.00608	0.0496	CbGeAlD
Clodronate—SLC25A5—urethra—urinary bladder cancer	0.00597	0.0487	CbGeAlD
Clodronate—SLC25A5—Azacitidine—Gemcitabine—urinary bladder cancer	0.00572	1	CbGdCrCtD
Clodronate—SLC25A4—renal system—urinary bladder cancer	0.0057	0.0465	CbGeAlD
Clodronate—SLC25A6—female reproductive system—urinary bladder cancer	0.0056	0.0456	CbGeAlD
Clodronate—SLC25A5—female reproductive system—urinary bladder cancer	0.00487	0.0397	CbGeAlD
Clodronate—SLC25A4—female reproductive system—urinary bladder cancer	0.00456	0.0372	CbGeAlD
Clodronate—SLC25A5—vagina—urinary bladder cancer	0.0044	0.0359	CbGeAlD
Clodronate—SLC25A4—vagina—urinary bladder cancer	0.00413	0.0336	CbGeAlD
Clodronate—SLC25A6—lymph node—urinary bladder cancer	0.00327	0.0267	CbGeAlD
Clodronate—SLC25A5—lymph node—urinary bladder cancer	0.00285	0.0232	CbGeAlD
Clodronate—SLC25A4—lymph node—urinary bladder cancer	0.00267	0.0218	CbGeAlD
Clodronate—PTGS2—prostate gland—urinary bladder cancer	0.00168	0.0137	CbGeAlD
Clodronate—PTGS2—seminal vesicle—urinary bladder cancer	0.00142	0.0116	CbGeAlD
Clodronate—PTGS2—epithelium—urinary bladder cancer	0.00123	0.0101	CbGeAlD
Clodronate—PTGS2—smooth muscle tissue—urinary bladder cancer	0.00119	0.0097	CbGeAlD
Clodronate—PTGS2—renal system—urinary bladder cancer	0.00114	0.00933	CbGeAlD
Clodronate—PTGS2—urethra—urinary bladder cancer	0.00112	0.00917	CbGeAlD
Clodronate—Creatinine increased—Gemcitabine—urinary bladder cancer	0.00108	0.00581	CcSEcCtD
Clodronate—Extravasation—Etoposide—urinary bladder cancer	0.001	0.00541	CcSEcCtD
Clodronate—Abdominal pain—Valrubicin—urinary bladder cancer	0.00099	0.00535	CcSEcCtD
Clodronate—Anaemia—Mitomycin—urinary bladder cancer	0.000977	0.00528	CcSEcCtD
Clodronate—Hepatocellular injury—Cisplatin—urinary bladder cancer	0.000954	0.00515	CcSEcCtD
Clodronate—Wheezing—Cisplatin—urinary bladder cancer	0.000926	0.00501	CcSEcCtD
Clodronate—PTGS2—female reproductive system—urinary bladder cancer	0.000917	0.00748	CbGeAlD
Clodronate—Cardiac failure—Thiotepa—urinary bladder cancer	0.000905	0.00489	CcSEcCtD
Clodronate—Pruritus—Valrubicin—urinary bladder cancer	0.000886	0.00479	CcSEcCtD
Clodronate—Local reaction—Epirubicin—urinary bladder cancer	0.000885	0.00478	CcSEcCtD
Clodronate—Diarrhoea—Valrubicin—urinary bladder cancer	0.000857	0.00463	CcSEcCtD
Clodronate—Hepatic function abnormal—Gemcitabine—urinary bladder cancer	0.00085	0.00459	CcSEcCtD
Clodronate—PTGS2—vagina—urinary bladder cancer	0.000829	0.00676	CbGeAlD
Clodronate—Blood creatinine increased—Thiotepa—urinary bladder cancer	0.000827	0.00447	CcSEcCtD
Clodronate—Anorexia—Mitomycin—urinary bladder cancer	0.000823	0.00445	CcSEcCtD
Clodronate—Dehydration—Thiotepa—urinary bladder cancer	0.000821	0.00444	CcSEcCtD
Clodronate—Local reaction—Doxorubicin—urinary bladder cancer	0.000819	0.00442	CcSEcCtD
Clodronate—Vomiting—Valrubicin—urinary bladder cancer	0.000796	0.0043	CcSEcCtD
Clodronate—Serum creatinine increased—Epirubicin—urinary bladder cancer	0.000796	0.0043	CcSEcCtD
Clodronate—Rash—Valrubicin—urinary bladder cancer	0.00079	0.00427	CcSEcCtD
Clodronate—Dermatitis—Valrubicin—urinary bladder cancer	0.000789	0.00426	CcSEcCtD
Clodronate—Renal impairment—Gemcitabine—urinary bladder cancer	0.000781	0.00422	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Thiotepa—urinary bladder cancer	0.000779	0.00421	CcSEcCtD
Clodronate—Dyspnoea—Mitomycin—urinary bladder cancer	0.000769	0.00416	CcSEcCtD
Clodronate—Liver disorder—Methotrexate—urinary bladder cancer	0.000768	0.00415	CcSEcCtD
Clodronate—Cardiac failure—Gemcitabine—urinary bladder cancer	0.000761	0.00411	CcSEcCtD
Clodronate—Decreased appetite—Mitomycin—urinary bladder cancer	0.00075	0.00405	CcSEcCtD
Clodronate—Renal failure acute—Cisplatin—urinary bladder cancer	0.00075	0.00405	CcSEcCtD
Clodronate—Cardiac failure—Fluorouracil—urinary bladder cancer	0.000748	0.00404	CcSEcCtD
Clodronate—Nausea—Valrubicin—urinary bladder cancer	0.000744	0.00402	CcSEcCtD
Clodronate—Serum creatinine increased—Doxorubicin—urinary bladder cancer	0.000737	0.00398	CcSEcCtD
Clodronate—Hypercalcaemia—Epirubicin—urinary bladder cancer	0.000705	0.00381	CcSEcCtD
Clodronate—Blood creatinine increased—Gemcitabine—urinary bladder cancer	0.000696	0.00376	CcSEcCtD
Clodronate—Pneumonia—Thiotepa—urinary bladder cancer	0.000684	0.0037	CcSEcCtD
Clodronate—Renal failure—Thiotepa—urinary bladder cancer	0.000669	0.00361	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Gemcitabine—urinary bladder cancer	0.000655	0.00354	CcSEcCtD
Clodronate—Hypercalcaemia—Doxorubicin—urinary bladder cancer	0.000652	0.00353	CcSEcCtD
Clodronate—Cardiac failure—Etoposide—urinary bladder cancer	0.00065	0.00351	CcSEcCtD
Clodronate—Blood creatinine increased—Cisplatin—urinary bladder cancer	0.000649	0.00351	CcSEcCtD
Clodronate—Dehydration—Cisplatin—urinary bladder cancer	0.000644	0.00348	CcSEcCtD
Clodronate—Bronchospasm—Gemcitabine—urinary bladder cancer	0.000632	0.00341	CcSEcCtD
Clodronate—Dysphagia—Fluorouracil—urinary bladder cancer	0.000631	0.00341	CcSEcCtD
Clodronate—Urinary tract disorder—Thiotepa—urinary bladder cancer	0.000603	0.00326	CcSEcCtD
Clodronate—Connective tissue disorder—Thiotepa—urinary bladder cancer	0.0006	0.00324	CcSEcCtD
Clodronate—Extravasation—Methotrexate—urinary bladder cancer	0.0006	0.00324	CcSEcCtD
Clodronate—Urethral disorder—Thiotepa—urinary bladder cancer	0.000599	0.00324	CcSEcCtD
Clodronate—Proteinuria—Methotrexate—urinary bladder cancer	0.000596	0.00322	CcSEcCtD
Clodronate—Diarrhoea—Mitomycin—urinary bladder cancer	0.00059	0.00319	CcSEcCtD
Clodronate—Protein urine present—Methotrexate—urinary bladder cancer	0.000587	0.00317	CcSEcCtD
Clodronate—Pneumonia—Gemcitabine—urinary bladder cancer	0.000576	0.00311	CcSEcCtD
Clodronate—Neoplasm malignant—Epirubicin—urinary bladder cancer	0.000574	0.0031	CcSEcCtD
Clodronate—Oliguria—Methotrexate—urinary bladder cancer	0.000568	0.00307	CcSEcCtD
Clodronate—Pneumonia—Fluorouracil—urinary bladder cancer	0.000566	0.00306	CcSEcCtD
Clodronate—Renal failure—Gemcitabine—urinary bladder cancer	0.000563	0.00304	CcSEcCtD
Clodronate—Extravasation—Epirubicin—urinary bladder cancer	0.000561	0.00303	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Etoposide—urinary bladder cancer	0.000559	0.00302	CcSEcCtD
Clodronate—Mediastinal disorder—Thiotepa—urinary bladder cancer	0.000551	0.00298	CcSEcCtD
Clodronate—Vomiting—Mitomycin—urinary bladder cancer	0.000549	0.00297	CcSEcCtD
Clodronate—Dysphagia—Etoposide—urinary bladder cancer	0.000548	0.00296	CcSEcCtD
Clodronate—Rash—Mitomycin—urinary bladder cancer	0.000544	0.00294	CcSEcCtD
Clodronate—Dermatitis—Mitomycin—urinary bladder cancer	0.000544	0.00294	CcSEcCtD
Clodronate—Bronchospasm—Etoposide—urinary bladder cancer	0.000539	0.00291	CcSEcCtD
Clodronate—PTGS2—lymph node—urinary bladder cancer	0.000536	0.00437	CbGeAlD
Clodronate—Hypocalcaemia—Epirubicin—urinary bladder cancer	0.000535	0.00289	CcSEcCtD
Clodronate—Oliguria—Epirubicin—urinary bladder cancer	0.000532	0.00287	CcSEcCtD
Clodronate—Neoplasm malignant—Doxorubicin—urinary bladder cancer	0.000531	0.00287	CcSEcCtD
Clodronate—Renal failure—Cisplatin—urinary bladder cancer	0.000524	0.00283	CcSEcCtD
Clodronate—Extravasation—Doxorubicin—urinary bladder cancer	0.000519	0.00281	CcSEcCtD
Clodronate—Creatinine increased—Epirubicin—urinary bladder cancer	0.000515	0.00278	CcSEcCtD
Clodronate—Nausea—Mitomycin—urinary bladder cancer	0.000513	0.00277	CcSEcCtD
Clodronate—Pharyngitis—Gemcitabine—urinary bladder cancer	0.00051	0.00276	CcSEcCtD
Clodronate—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.000507	0.00274	CcSEcCtD
Clodronate—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.000505	0.00273	CcSEcCtD
Clodronate—Urethral disorder—Gemcitabine—urinary bladder cancer	0.000504	0.00272	CcSEcCtD
Clodronate—Pharyngitis—Fluorouracil—urinary bladder cancer	0.000501	0.00271	CcSEcCtD
Clodronate—Hypocalcaemia—Doxorubicin—urinary bladder cancer	0.000495	0.00268	CcSEcCtD
Clodronate—Oliguria—Doxorubicin—urinary bladder cancer	0.000492	0.00266	CcSEcCtD
Clodronate—Pneumonia—Etoposide—urinary bladder cancer	0.000492	0.00266	CcSEcCtD
Clodronate—Anaemia—Thiotepa—urinary bladder cancer	0.000492	0.00266	CcSEcCtD
Clodronate—Hepatocellular injury—Epirubicin—urinary bladder cancer	0.00049	0.00265	CcSEcCtD
Clodronate—Renal failure—Etoposide—urinary bladder cancer	0.000481	0.0026	CcSEcCtD
Clodronate—Creatinine increased—Doxorubicin—urinary bladder cancer	0.000476	0.00257	CcSEcCtD
Clodronate—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.000473	0.00256	CcSEcCtD
Clodronate—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.000471	0.00254	CcSEcCtD
Clodronate—Urethral disorder—Cisplatin—urinary bladder cancer	0.00047	0.00254	CcSEcCtD
Clodronate—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.000463	0.0025	CcSEcCtD
Clodronate—Hepatocellular injury—Doxorubicin—urinary bladder cancer	0.000453	0.00245	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00045	0.00243	CcSEcCtD
Clodronate—Urinary tract disorder—Etoposide—urinary bladder cancer	0.000433	0.00234	CcSEcCtD
Clodronate—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.000432	0.00233	CcSEcCtD
Clodronate—Infection—Thiotepa—urinary bladder cancer	0.000431	0.00233	CcSEcCtD
Clodronate—Urethral disorder—Etoposide—urinary bladder cancer	0.00043	0.00232	CcSEcCtD
Clodronate—Skin disorder—Thiotepa—urinary bladder cancer	0.000422	0.00228	CcSEcCtD
Clodronate—Anorexia—Thiotepa—urinary bladder cancer	0.000414	0.00224	CcSEcCtD
Clodronate—Anaemia—Gemcitabine—urinary bladder cancer	0.000413	0.00223	CcSEcCtD
Clodronate—Renal failure acute—Methotrexate—urinary bladder cancer	0.000412	0.00222	CcSEcCtD
Clodronate—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.000407	0.0022	CcSEcCtD
Clodronate—Anaemia—Fluorouracil—urinary bladder cancer	0.000407	0.0022	CcSEcCtD
Clodronate—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000395	0.00214	CcSEcCtD
Clodronate—Anaemia—Cisplatin—urinary bladder cancer	0.000385	0.00208	CcSEcCtD
Clodronate—Renal failure acute—Epirubicin—urinary bladder cancer	0.000385	0.00208	CcSEcCtD
Clodronate—Dyspepsia—Thiotepa—urinary bladder cancer	0.000382	0.00206	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000378	0.00204	CcSEcCtD
Clodronate—Decreased appetite—Thiotepa—urinary bladder cancer	0.000377	0.00204	CcSEcCtD
Clodronate—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.000376	0.00203	CcSEcCtD
Clodronate—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000375	0.00202	CcSEcCtD
Clodronate—Renal impairment—Epirubicin—urinary bladder cancer	0.000374	0.00202	CcSEcCtD
Clodronate—Cardiac failure—Epirubicin—urinary bladder cancer	0.000364	0.00197	CcSEcCtD
Clodronate—Infection—Gemcitabine—urinary bladder cancer	0.000363	0.00196	CcSEcCtD
Clodronate—Infection—Fluorouracil—urinary bladder cancer	0.000357	0.00193	CcSEcCtD
Clodronate—Renal failure acute—Doxorubicin—urinary bladder cancer	0.000356	0.00193	CcSEcCtD
Clodronate—Skin disorder—Gemcitabine—urinary bladder cancer	0.000355	0.00192	CcSEcCtD
Clodronate—Anaemia—Etoposide—urinary bladder cancer	0.000353	0.00191	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000353	0.00191	CcSEcCtD
Clodronate—Anorexia—Gemcitabine—urinary bladder cancer	0.000348	0.00188	CcSEcCtD
Clodronate—Renal impairment—Doxorubicin—urinary bladder cancer	0.000346	0.00187	CcSEcCtD
Clodronate—Urticaria—Thiotepa—urinary bladder cancer	0.000345	0.00186	CcSEcCtD
Clodronate—Abdominal pain—Thiotepa—urinary bladder cancer	0.000343	0.00185	CcSEcCtD
Clodronate—Anorexia—Fluorouracil—urinary bladder cancer	0.000342	0.00185	CcSEcCtD
Clodronate—Infection—Cisplatin—urinary bladder cancer	0.000338	0.00183	CcSEcCtD
Clodronate—Cardiac failure—Doxorubicin—urinary bladder cancer	0.000337	0.00182	CcSEcCtD
Clodronate—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.000333	0.0018	CcSEcCtD
Clodronate—Dehydration—Epirubicin—urinary bladder cancer	0.000331	0.00179	CcSEcCtD
Clodronate—Skin disorder—Cisplatin—urinary bladder cancer	0.000331	0.00179	CcSEcCtD
Clodronate—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000325	0.00176	CcSEcCtD
Clodronate—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000325	0.00175	CcSEcCtD
Clodronate—Anorexia—Cisplatin—urinary bladder cancer	0.000324	0.00175	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000323	0.00175	CcSEcCtD
Clodronate—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00032	0.00173	CcSEcCtD
Clodronate—SLC25A4—Metabolism—CYP4B1—urinary bladder cancer	0.000318	0.00445	CbGpPWpGaD
Clodronate—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000317	0.00172	CcSEcCtD
Clodronate—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000316	0.00171	CcSEcCtD
Clodronate—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000315	0.0017	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000314	0.00169	CcSEcCtD
Clodronate—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000312	0.00169	CcSEcCtD
Clodronate—PTGS2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000311	0.00435	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.00031	0.00434	CbGpPWpGaD
Clodronate—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00031	0.00167	CcSEcCtD
Clodronate—Infection—Etoposide—urinary bladder cancer	0.00031	0.00167	CcSEcCtD
Clodronate—SLC25A5—Disease—ENO2—urinary bladder cancer	0.000309	0.00432	CbGpPWpGaD
Clodronate—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000308	0.00167	CcSEcCtD
Clodronate—Dysphagia—Epirubicin—urinary bladder cancer	0.000307	0.00166	CcSEcCtD
Clodronate—Pruritus—Thiotepa—urinary bladder cancer	0.000307	0.00166	CcSEcCtD
Clodronate—Dehydration—Doxorubicin—urinary bladder cancer	0.000306	0.00165	CcSEcCtD
Clodronate—Dyspnoea—Cisplatin—urinary bladder cancer	0.000303	0.00164	CcSEcCtD
Clodronate—Skin disorder—Etoposide—urinary bladder cancer	0.000303	0.00164	CcSEcCtD
Clodronate—SLC25A4—Metabolism—SLC19A1—urinary bladder cancer	0.000301	0.0042	CbGpPWpGaD
Clodronate—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.0003	0.00162	CcSEcCtD
Clodronate—SLC25A6—Metabolism—TYMP—urinary bladder cancer	0.0003	0.00419	CbGpPWpGaD
Clodronate—Anorexia—Etoposide—urinary bladder cancer	0.000297	0.00161	CcSEcCtD
Clodronate—Diarrhoea—Thiotepa—urinary bladder cancer	0.000297	0.0016	CcSEcCtD
Clodronate—Decreased appetite—Cisplatin—urinary bladder cancer	0.000296	0.0016	CcSEcCtD
Clodronate—Pneumonia—Methotrexate—urinary bladder cancer	0.000294	0.00159	CcSEcCtD
Clodronate—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000294	0.00159	CcSEcCtD
Clodronate—SLC25A5—Disease—RBX1—urinary bladder cancer	0.000293	0.0041	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PRSS3—urinary bladder cancer	0.000293	0.0041	CbGpPWpGaD
Clodronate—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.00029	0.00157	CcSEcCtD
Clodronate—Renal failure—Methotrexate—urinary bladder cancer	0.000288	0.00156	CcSEcCtD
Clodronate—Urticaria—Fluorouracil—urinary bladder cancer	0.000285	0.00154	CcSEcCtD
Clodronate—Dysphagia—Doxorubicin—urinary bladder cancer	0.000284	0.00154	CcSEcCtD
Clodronate—SLC25A5—Metabolism—RRM2—urinary bladder cancer	0.00028	0.00391	CbGpPWpGaD
Clodronate—Dyspnoea—Etoposide—urinary bladder cancer	0.000278	0.0015	CcSEcCtD
Clodronate—Vomiting—Thiotepa—urinary bladder cancer	0.000276	0.00149	CcSEcCtD
Clodronate—Pneumonia—Epirubicin—urinary bladder cancer	0.000276	0.00149	CcSEcCtD
Clodronate—Rash—Thiotepa—urinary bladder cancer	0.000274	0.00148	CcSEcCtD
Clodronate—Dermatitis—Thiotepa—urinary bladder cancer	0.000273	0.00148	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000273	0.00381	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—NAT2—urinary bladder cancer	0.000271	0.00379	CbGpPWpGaD
Clodronate—Decreased appetite—Etoposide—urinary bladder cancer	0.000271	0.00146	CcSEcCtD
Clodronate—Renal failure—Epirubicin—urinary bladder cancer	0.000269	0.00146	CcSEcCtD
Clodronate—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000269	0.00145	CcSEcCtD
Clodronate—PTGS2—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000268	0.00375	CbGpPWpGaD
Clodronate—SLC25A4—Disease—LIG1—urinary bladder cancer	0.000265	0.00371	CbGpPWpGaD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—urinary bladder cancer	0.000263	0.00367	CbGpPWpGaD
Clodronate—SLC25A5—Disease—JAG1—urinary bladder cancer	0.000262	0.00367	CbGpPWpGaD
Clodronate—Pharyngitis—Methotrexate—urinary bladder cancer	0.000261	0.00141	CcSEcCtD
Clodronate—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.00026	0.0014	CcSEcCtD
Clodronate—SLC25A6—Disease—ENO2—urinary bladder cancer	0.000259	0.00362	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—HPGDS—urinary bladder cancer	0.000259	0.00362	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—ENO2—urinary bladder cancer	0.000259	0.00362	CbGpPWpGaD
Clodronate—Pruritus—Gemcitabine—urinary bladder cancer	0.000258	0.0014	CcSEcCtD
Clodronate—Nausea—Thiotepa—urinary bladder cancer	0.000258	0.00139	CcSEcCtD
Clodronate—Urethral disorder—Methotrexate—urinary bladder cancer	0.000258	0.00139	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—urinary bladder cancer	0.000256	0.00358	CbGpPWpGaD
Clodronate—Pneumonia—Doxorubicin—urinary bladder cancer	0.000255	0.00138	CcSEcCtD
Clodronate—Pruritus—Fluorouracil—urinary bladder cancer	0.000254	0.00137	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000252	0.00352	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—GSTT1—urinary bladder cancer	0.000251	0.00351	CbGpPWpGaD
Clodronate—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00025	0.00135	CcSEcCtD
Clodronate—Renal failure—Doxorubicin—urinary bladder cancer	0.000249	0.00135	CcSEcCtD
Clodronate—Urticaria—Etoposide—urinary bladder cancer	0.000248	0.00134	CcSEcCtD
Clodronate—Abdominal pain—Etoposide—urinary bladder cancer	0.000246	0.00133	CcSEcCtD
Clodronate—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000246	0.00133	CcSEcCtD
Clodronate—SLC25A6—Disease—RBX1—urinary bladder cancer	0.000246	0.00343	CbGpPWpGaD
Clodronate—Pharyngitis—Epirubicin—urinary bladder cancer	0.000244	0.00132	CcSEcCtD
Clodronate—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000243	0.00131	CcSEcCtD
Clodronate—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000242	0.00131	CcSEcCtD
Clodronate—Urethral disorder—Epirubicin—urinary bladder cancer	0.000241	0.0013	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000238	0.00333	CbGpPWpGaD
Clodronate—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000237	0.00128	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000236	0.0033	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—TYMP—urinary bladder cancer	0.000234	0.00327	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—RRM2—urinary bladder cancer	0.000234	0.00327	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—urinary bladder cancer	0.000233	0.00326	CbGpPWpGaD
Clodronate—Diarrhoea—Cisplatin—urinary bladder cancer	0.000233	0.00126	CcSEcCtD
Clodronate—Vomiting—Gemcitabine—urinary bladder cancer	0.000232	0.00125	CcSEcCtD
Clodronate—Rash—Gemcitabine—urinary bladder cancer	0.00023	0.00124	CcSEcCtD
Clodronate—Dermatitis—Gemcitabine—urinary bladder cancer	0.00023	0.00124	CcSEcCtD
Clodronate—Vomiting—Fluorouracil—urinary bladder cancer	0.000228	0.00123	CcSEcCtD
Clodronate—Rash—Fluorouracil—urinary bladder cancer	0.000226	0.00122	CcSEcCtD
Clodronate—Dermatitis—Fluorouracil—urinary bladder cancer	0.000226	0.00122	CcSEcCtD
Clodronate—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000226	0.00122	CcSEcCtD
Clodronate—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000225	0.00121	CcSEcCtD
Clodronate—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000224	0.00121	CcSEcCtD
Clodronate—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000223	0.00121	CcSEcCtD
Clodronate—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000222	0.0012	CcSEcCtD
Clodronate—Pruritus—Etoposide—urinary bladder cancer	0.000221	0.00119	CcSEcCtD
Clodronate—SLC25A6—Disease—JAG1—urinary bladder cancer	0.00022	0.00307	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—HPGDS—urinary bladder cancer	0.000217	0.00303	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—ENO2—urinary bladder cancer	0.000217	0.00303	CbGpPWpGaD
Clodronate—Nausea—Gemcitabine—urinary bladder cancer	0.000217	0.00117	CcSEcCtD
Clodronate—Vomiting—Cisplatin—urinary bladder cancer	0.000216	0.00117	CcSEcCtD
Clodronate—PTGS2—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.000215	0.003	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—NCOR1—urinary bladder cancer	0.000215	0.003	CbGpPWpGaD
Clodronate—Rash—Cisplatin—urinary bladder cancer	0.000215	0.00116	CcSEcCtD
Clodronate—Dermatitis—Cisplatin—urinary bladder cancer	0.000214	0.00116	CcSEcCtD
Clodronate—Diarrhoea—Etoposide—urinary bladder cancer	0.000213	0.00115	CcSEcCtD
Clodronate—Nausea—Fluorouracil—urinary bladder cancer	0.000213	0.00115	CcSEcCtD
Clodronate—SLC25A4—Metabolism—NAT2—urinary bladder cancer	0.000212	0.00296	CbGpPWpGaD
Clodronate—Anaemia—Methotrexate—urinary bladder cancer	0.000211	0.00114	CcSEcCtD
Clodronate—SLC25A6—Metabolism—GSTT1—urinary bladder cancer	0.00021	0.00294	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—NQO1—urinary bladder cancer	0.000209	0.00292	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000208	0.0029	CbGpPWpGaD
Clodronate—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000205	0.00111	CcSEcCtD
Clodronate—SLC25A4—Disease—ENO2—urinary bladder cancer	0.000202	0.00283	CbGpPWpGaD
Clodronate—Nausea—Cisplatin—urinary bladder cancer	0.000202	0.00109	CcSEcCtD
Clodronate—Vomiting—Etoposide—urinary bladder cancer	0.000198	0.00107	CcSEcCtD
Clodronate—PTGS2—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000198	0.00277	CbGpPWpGaD
Clodronate—Anaemia—Epirubicin—urinary bladder cancer	0.000198	0.00107	CcSEcCtD
Clodronate—Rash—Etoposide—urinary bladder cancer	0.000197	0.00106	CcSEcCtD
Clodronate—Dermatitis—Etoposide—urinary bladder cancer	0.000196	0.00106	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000193	0.00105	CcSEcCtD
Clodronate—SLC25A4—Disease—RBX1—urinary bladder cancer	0.000192	0.00268	CbGpPWpGaD
Clodronate—SLC25A5—Disease—NCOR1—urinary bladder cancer	0.000191	0.00267	CbGpPWpGaD
Clodronate—Infection—Methotrexate—urinary bladder cancer	0.000186	0.001	CcSEcCtD
Clodronate—Nausea—Etoposide—urinary bladder cancer	0.000185	0.001	CcSEcCtD
Clodronate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.000184	0.00258	CbGpPWpGaD
Clodronate—Anaemia—Doxorubicin—urinary bladder cancer	0.000183	0.00099	CcSEcCtD
Clodronate—SLC25A4—Metabolism—RRM2—urinary bladder cancer	0.000183	0.00256	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000183	0.00255	CbGpPWpGaD
Clodronate—Skin disorder—Methotrexate—urinary bladder cancer	0.000181	0.00098	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000181	0.000978	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.00018	0.00252	CbGpPWpGaD
Clodronate—SLC25A5—Disease—ERCC2—urinary bladder cancer	0.00018	0.00251	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000179	0.0025	CbGpPWpGaD
Clodronate—Anorexia—Methotrexate—urinary bladder cancer	0.000178	0.000962	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—urinary bladder cancer	0.000178	0.00248	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—IGF1—urinary bladder cancer	0.000177	0.00247	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—NQO1—urinary bladder cancer	0.000175	0.00244	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—GSTP1—urinary bladder cancer	0.000174	0.00243	CbGpPWpGaD
Clodronate—Infection—Epirubicin—urinary bladder cancer	0.000174	0.000938	CcSEcCtD
Clodronate—SLC25A4—Disease—JAG1—urinary bladder cancer	0.000172	0.0024	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000171	0.00239	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—urinary bladder cancer	0.00017	0.00237	CbGpPWpGaD
Clodronate—Skin disorder—Epirubicin—urinary bladder cancer	0.00017	0.000917	CcSEcCtD
Clodronate—SLC25A4—Metabolism—ENO2—urinary bladder cancer	0.000169	0.00237	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—HPGDS—urinary bladder cancer	0.000169	0.00237	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MTHFR—urinary bladder cancer	0.000169	0.00236	CbGpPWpGaD
Clodronate—SLC25A5—Disease—TERT—urinary bladder cancer	0.000168	0.00235	CbGpPWpGaD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000168	0.000905	CcSEcCtD
Clodronate—Anorexia—Epirubicin—urinary bladder cancer	0.000167	0.0009	CcSEcCtD
Clodronate—Dyspnoea—Methotrexate—urinary bladder cancer	0.000166	0.0009	CcSEcCtD
Clodronate—Dyspepsia—Methotrexate—urinary bladder cancer	0.000164	0.000888	CcSEcCtD
Clodronate—SLC25A4—Metabolism—GSTT1—urinary bladder cancer	0.000164	0.0023	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000163	0.00228	CbGpPWpGaD
Clodronate—Decreased appetite—Methotrexate—urinary bladder cancer	0.000162	0.000877	CcSEcCtD
Clodronate—SLC25A5—Metabolism—TYMS—urinary bladder cancer	0.000162	0.00226	CbGpPWpGaD
Clodronate—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000161	0.000871	CcSEcCtD
Clodronate—Infection—Doxorubicin—urinary bladder cancer	0.000161	0.000868	CcSEcCtD
Clodronate—SLC25A6—Disease—NCOR1—urinary bladder cancer	0.00016	0.00224	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—GSTM1—urinary bladder cancer	0.00016	0.00224	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—NCOR1—urinary bladder cancer	0.00016	0.00224	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000158	0.00221	CbGpPWpGaD
Clodronate—Skin disorder—Doxorubicin—urinary bladder cancer	0.000157	0.000849	CcSEcCtD
Clodronate—Dyspnoea—Epirubicin—urinary bladder cancer	0.000156	0.000842	CcSEcCtD
Clodronate—SLC25A5—Disease—FGFR3—urinary bladder cancer	0.000154	0.00216	CbGpPWpGaD
Clodronate—Anorexia—Doxorubicin—urinary bladder cancer	0.000154	0.000833	CcSEcCtD
Clodronate—Dyspepsia—Epirubicin—urinary bladder cancer	0.000154	0.000831	CcSEcCtD
Clodronate—SLC25A5—Metabolism—GPX1—urinary bladder cancer	0.000153	0.00214	CbGpPWpGaD
Clodronate—Decreased appetite—Epirubicin—urinary bladder cancer	0.000152	0.000821	CcSEcCtD
Clodronate—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000151	0.000815	CcSEcCtD
Clodronate—SLC25A6—Disease—ERCC2—urinary bladder cancer	0.00015	0.0021	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—ERCC2—urinary bladder cancer	0.00015	0.0021	CbGpPWpGaD
Clodronate—Urticaria—Methotrexate—urinary bladder cancer	0.000148	0.000802	CcSEcCtD
Clodronate—PTGS2—C-MYB transcription factor network—CREBBP—urinary bladder cancer	0.000148	0.00207	CbGpPWpGaD
Clodronate—Abdominal pain—Methotrexate—urinary bladder cancer	0.000148	0.000798	CcSEcCtD
Clodronate—SLC25A6—Metabolism—GSTP1—urinary bladder cancer	0.000146	0.00204	CbGpPWpGaD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	0.000145	0.00203	CbGpPWpGaD
Clodronate—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000144	0.000779	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000144	0.00201	CbGpPWpGaD
Clodronate—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000142	0.000769	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—CXCL8—urinary bladder cancer	0.000142	0.00199	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000142	0.00198	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MTHFR—urinary bladder cancer	0.000141	0.00198	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—MTHFR—urinary bladder cancer	0.000141	0.00198	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000141	0.00198	CbGpPWpGaD
Clodronate—SLC25A6—Disease—TERT—urinary bladder cancer	0.000141	0.00197	CbGpPWpGaD
Clodronate—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000141	0.00076	CcSEcCtD
Clodronate—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00014	0.000754	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000139	0.00194	CbGpPWpGaD
Clodronate—Urticaria—Epirubicin—urinary bladder cancer	0.000139	0.00075	CcSEcCtD
Clodronate—Abdominal pain—Epirubicin—urinary bladder cancer	0.000138	0.000747	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—IGF1—urinary bladder cancer	0.000138	0.00193	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—NQO1—urinary bladder cancer	0.000137	0.00191	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—TYMS—urinary bladder cancer	0.000136	0.0019	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—NCOR1—urinary bladder cancer	0.000134	0.00187	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—GSTM1—urinary bladder cancer	0.000134	0.00187	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000132	0.00185	CbGpPWpGaD
Clodronate—Pruritus—Methotrexate—urinary bladder cancer	0.000132	0.000714	CcSEcCtD
Clodronate—SLC25A5—Disease—CREBBP—urinary bladder cancer	0.000131	0.00184	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000131	0.00183	CbGpPWpGaD
Clodronate—SLC25A6—Disease—FGFR3—urinary bladder cancer	0.000129	0.00181	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	0.000129	0.00181	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CDK4—urinary bladder cancer	0.000129	0.0018	CbGpPWpGaD
Clodronate—Urticaria—Doxorubicin—urinary bladder cancer	0.000128	0.000694	CcSEcCtD
Clodronate—SLC25A6—Metabolism—GPX1—urinary bladder cancer	0.000128	0.00179	CbGpPWpGaD
Clodronate—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000128	0.000691	CcSEcCtD
Clodronate—Diarrhoea—Methotrexate—urinary bladder cancer	0.000128	0.00069	CcSEcCtD
Clodronate—SLC25A6—Metabolism—ERCC2—urinary bladder cancer	0.000126	0.00176	CbGpPWpGaD
Clodronate—SLC25A4—Disease—NCOR1—urinary bladder cancer	0.000125	0.00175	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—urinary bladder cancer	0.000124	0.00173	CbGpPWpGaD
Clodronate—Pruritus—Epirubicin—urinary bladder cancer	0.000124	0.000668	CcSEcCtD
Clodronate—Diarrhoea—Epirubicin—urinary bladder cancer	0.00012	0.000646	CcSEcCtD
Clodronate—SLC25A5—Disease—RHOA—urinary bladder cancer	0.000119	0.00166	CbGpPWpGaD
Clodronate—Vomiting—Methotrexate—urinary bladder cancer	0.000119	0.000642	CcSEcCtD
Clodronate—SLC25A6—Metabolism—MTHFR—urinary bladder cancer	0.000118	0.00166	CbGpPWpGaD
Clodronate—Rash—Methotrexate—urinary bladder cancer	0.000118	0.000636	CcSEcCtD
Clodronate—Dermatitis—Methotrexate—urinary bladder cancer	0.000118	0.000636	CcSEcCtD
Clodronate—SLC25A4—Disease—ERCC2—urinary bladder cancer	0.000117	0.00164	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PPARG—urinary bladder cancer	0.000115	0.0016	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000115	0.0016	CbGpPWpGaD
Clodronate—Pruritus—Doxorubicin—urinary bladder cancer	0.000114	0.000618	CcSEcCtD
Clodronate—SLC25A4—Metabolism—GSTP1—urinary bladder cancer	0.000114	0.00159	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000113	0.00157	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	0.000112	0.00157	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000111	0.00156	CbGpPWpGaD
Clodronate—Vomiting—Epirubicin—urinary bladder cancer	0.000111	0.0006	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—CXCL8—urinary bladder cancer	0.000111	0.00155	CbGpPWpGaD
Clodronate—Nausea—Methotrexate—urinary bladder cancer	0.000111	0.000599	CcSEcCtD
Clodronate—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000111	0.000598	CcSEcCtD
Clodronate—SLC25A4—Disease—MTHFR—urinary bladder cancer	0.00011	0.00154	CbGpPWpGaD
Clodronate—Rash—Epirubicin—urinary bladder cancer	0.00011	0.000595	CcSEcCtD
Clodronate—SLC25A6—Disease—CREBBP—urinary bladder cancer	0.00011	0.00154	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—CREBBP—urinary bladder cancer	0.00011	0.00154	CbGpPWpGaD
Clodronate—SLC25A4—Disease—TERT—urinary bladder cancer	0.00011	0.00154	CbGpPWpGaD
Clodronate—SLC25A5—Disease—ERBB2—urinary bladder cancer	0.00011	0.00154	CbGpPWpGaD
Clodronate—Dermatitis—Epirubicin—urinary bladder cancer	0.00011	0.000595	CcSEcCtD
Clodronate—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	0.000109	0.00153	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PTGS2—urinary bladder cancer	0.000108	0.0015	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—TYMS—urinary bladder cancer	0.000106	0.00148	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	0.000106	0.00148	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—NCOR1—urinary bladder cancer	0.000105	0.00146	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—GSTM1—urinary bladder cancer	0.000105	0.00146	CbGpPWpGaD
Clodronate—Nausea—Epirubicin—urinary bladder cancer	0.000104	0.000561	CcSEcCtD
Clodronate—Vomiting—Doxorubicin—urinary bladder cancer	0.000103	0.000556	CcSEcCtD
Clodronate—Rash—Doxorubicin—urinary bladder cancer	0.000102	0.000551	CcSEcCtD
Clodronate—Dermatitis—Doxorubicin—urinary bladder cancer	0.000102	0.00055	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	0.000102	0.00142	CbGpPWpGaD
Clodronate—SLC25A4—Disease—FGFR3—urinary bladder cancer	0.000101	0.00141	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	0.000101	0.00141	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—GPX1—urinary bladder cancer	0.0001	0.0014	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	9.97e-05	0.00139	CbGpPWpGaD
Clodronate—SLC25A6—Disease—RHOA—urinary bladder cancer	9.97e-05	0.00139	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—ERCC2—urinary bladder cancer	9.84e-05	0.00138	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PPARG—urinary bladder cancer	9.6e-05	0.00134	CbGpPWpGaD
Clodronate—Nausea—Doxorubicin—urinary bladder cancer	9.6e-05	0.000519	CcSEcCtD
Clodronate—SLC25A5—Disease—CDKN1A—urinary bladder cancer	9.41e-05	0.00132	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PTEN—urinary bladder cancer	9.39e-05	0.00131	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—MTHFR—urinary bladder cancer	9.25e-05	0.00129	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—CREBBP—urinary bladder cancer	9.23e-05	0.00129	CbGpPWpGaD
Clodronate—SLC25A6—Disease—ERBB2—urinary bladder cancer	9.23e-05	0.00129	CbGpPWpGaD
Clodronate—PTGS2—Disease—GSTO2—urinary bladder cancer	9.13e-05	0.00128	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PTGS2—urinary bladder cancer	9.02e-05	0.00126	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PTGS2—urinary bladder cancer	9.02e-05	0.00126	CbGpPWpGaD
Clodronate—SLC25A5—Disease—EP300—urinary bladder cancer	8.95e-05	0.00125	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	8.94e-05	0.00125	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	8.81e-05	0.00123	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	8.77e-05	0.00123	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	8.77e-05	0.00123	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	8.74e-05	0.00122	CbGpPWpGaD
Clodronate—SLC25A5—Disease—SRC—urinary bladder cancer	8.71e-05	0.00122	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CREBBP—urinary bladder cancer	8.6e-05	0.0012	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	8.54e-05	0.00119	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	8.33e-05	0.00116	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	8.1e-05	0.00113	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	8.09e-05	0.00113	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	8.06e-05	0.00113	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CDKN1A—urinary bladder cancer	7.89e-05	0.0011	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	7.87e-05	0.0011	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PTEN—urinary bladder cancer	7.87e-05	0.0011	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PTEN—urinary bladder cancer	7.86e-05	0.0011	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MYC—urinary bladder cancer	7.8e-05	0.00109	CbGpPWpGaD
Clodronate—SLC25A4—Disease—RHOA—urinary bladder cancer	7.78e-05	0.00109	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	7.66e-05	0.00107	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTO2—urinary bladder cancer	7.64e-05	0.00107	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NAT1—urinary bladder cancer	7.64e-05	0.00107	CbGpPWpGaD
Clodronate—SLC25A5—Disease—EGFR—urinary bladder cancer	7.63e-05	0.00107	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	7.56e-05	0.00106	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PTGS2—urinary bladder cancer	7.56e-05	0.00106	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.52e-05	0.00105	CbGpPWpGaD
Clodronate—SLC25A6—Disease—EP300—urinary bladder cancer	7.5e-05	0.00105	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—EP300—urinary bladder cancer	7.5e-05	0.00105	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PPARG—urinary bladder cancer	7.5e-05	0.00105	CbGpPWpGaD
Clodronate—SLC25A6—Disease—SRC—urinary bladder cancer	7.3e-05	0.00102	CbGpPWpGaD
Clodronate—SLC25A5—Disease—KRAS—urinary bladder cancer	7.21e-05	0.00101	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—CREBBP—urinary bladder cancer	7.2e-05	0.00101	CbGpPWpGaD
Clodronate—SLC25A4—Disease—ERBB2—urinary bladder cancer	7.2e-05	0.00101	CbGpPWpGaD
Clodronate—PTGS2—Disease—SLC19A1—urinary bladder cancer	7.1e-05	0.000992	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PTGS2—urinary bladder cancer	7.04e-05	0.000984	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	6.99e-05	0.000977	CbGpPWpGaD
Clodronate—PTGS2—Disease—PRSS3—urinary bladder cancer	6.92e-05	0.000967	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	6.89e-05	0.000963	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	6.68e-05	0.000934	CbGpPWpGaD
Clodronate—PTGS2—Disease—HDAC4—urinary bladder cancer	6.6e-05	0.000922	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PTEN—urinary bladder cancer	6.59e-05	0.000921	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MYC—urinary bladder cancer	6.54e-05	0.000914	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	6.53e-05	0.000913	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	6.41e-05	0.000896	CbGpPWpGaD
Clodronate—SLC25A6—Disease—EGFR—urinary bladder cancer	6.4e-05	0.000894	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	6.29e-05	0.00088	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—EP300—urinary bladder cancer	6.28e-05	0.000878	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	6.22e-05	0.00087	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CDKN1A—urinary bladder cancer	6.16e-05	0.000861	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PTEN—urinary bladder cancer	6.14e-05	0.000859	CbGpPWpGaD
Clodronate—SLC25A5—Disease—HRAS—urinary bladder cancer	6.13e-05	0.000857	CbGpPWpGaD
Clodronate—SLC25A6—Disease—KRAS—urinary bladder cancer	6.04e-05	0.000845	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	5.94e-05	0.000831	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PTGS2—urinary bladder cancer	5.9e-05	0.000824	CbGpPWpGaD
Clodronate—SLC25A4—Disease—EP300—urinary bladder cancer	5.86e-05	0.000819	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PRSS3—urinary bladder cancer	5.79e-05	0.00081	CbGpPWpGaD
Clodronate—SLC25A4—Disease—SRC—urinary bladder cancer	5.7e-05	0.000796	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	5.67e-05	0.000792	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	5.49e-05	0.000767	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	5.48e-05	0.000766	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	5.47e-05	0.000764	CbGpPWpGaD
Clodronate—PTGS2—Disease—LIG1—urinary bladder cancer	5.24e-05	0.000733	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	5.22e-05	0.000729	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PTEN—urinary bladder cancer	5.14e-05	0.000719	CbGpPWpGaD
Clodronate—SLC25A6—Disease—HRAS—urinary bladder cancer	5.14e-05	0.000718	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MYC—urinary bladder cancer	5.1e-05	0.000713	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	5.07e-05	0.000709	CbGpPWpGaD
Clodronate—SLC25A4—Disease—EGFR—urinary bladder cancer	4.99e-05	0.000698	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—EP300—urinary bladder cancer	4.91e-05	0.000686	CbGpPWpGaD
Clodronate—SLC25A4—Disease—KRAS—urinary bladder cancer	4.72e-05	0.000659	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.64e-05	0.000649	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—TYMP—urinary bladder cancer	4.63e-05	0.000647	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.54e-05	0.000635	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.45e-05	0.000622	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	4.45e-05	0.000621	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	4.23e-05	0.000592	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	4.2e-05	0.000587	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NAT2—urinary bladder cancer	4.19e-05	0.000585	CbGpPWpGaD
Clodronate—SLC25A4—Disease—HRAS—urinary bladder cancer	4.01e-05	0.00056	CbGpPWpGaD
Clodronate—PTGS2—Disease—ENO2—urinary bladder cancer	4e-05	0.000559	CbGpPWpGaD
Clodronate—PTGS2—Disease—RBX1—urinary bladder cancer	3.79e-05	0.00053	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.73e-05	0.000522	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—RRM2—urinary bladder cancer	3.62e-05	0.000505	CbGpPWpGaD
Clodronate—PTGS2—Disease—JAG1—urinary bladder cancer	3.39e-05	0.000474	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ENO2—urinary bladder cancer	3.35e-05	0.000468	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—HPGDS—urinary bladder cancer	3.35e-05	0.000468	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.33e-05	0.000465	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTT1—urinary bladder cancer	3.25e-05	0.000454	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.2e-05	0.000447	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NQO1—urinary bladder cancer	2.7e-05	0.000377	CbGpPWpGaD
Clodronate—PTGS2—Disease—NCOR1—urinary bladder cancer	2.47e-05	0.000345	CbGpPWpGaD
Clodronate—PTGS2—Disease—ERCC2—urinary bladder cancer	2.32e-05	0.000325	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.28e-05	0.000319	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTP1—urinary bladder cancer	2.25e-05	0.000315	CbGpPWpGaD
Clodronate—PTGS2—Disease—MTHFR—urinary bladder cancer	2.18e-05	0.000305	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.18e-05	0.000304	CbGpPWpGaD
Clodronate—PTGS2—Disease—TERT—urinary bladder cancer	2.18e-05	0.000304	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—TYMS—urinary bladder cancer	2.09e-05	0.000293	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NCOR1—urinary bladder cancer	2.07e-05	0.000289	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTM1—urinary bladder cancer	2.07e-05	0.000289	CbGpPWpGaD
Clodronate—PTGS2—Disease—FGFR3—urinary bladder cancer	2e-05	0.000279	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.98e-05	0.000277	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.94e-05	0.000272	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.83e-05	0.000256	CbGpPWpGaD
Clodronate—PTGS2—Disease—CREBBP—urinary bladder cancer	1.7e-05	0.000238	CbGpPWpGaD
Clodronate—PTGS2—Disease—RHOA—urinary bladder cancer	1.54e-05	0.000215	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PPARG—urinary bladder cancer	1.48e-05	0.000207	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CREBBP—urinary bladder cancer	1.42e-05	0.000199	CbGpPWpGaD
Clodronate—PTGS2—Disease—ERBB2—urinary bladder cancer	1.42e-05	0.000199	CbGpPWpGaD
Clodronate—PTGS2—Disease—CDKN1A—urinary bladder cancer	1.22e-05	0.00017	CbGpPWpGaD
Clodronate—PTGS2—Disease—PTEN—urinary bladder cancer	1.21e-05	0.00017	CbGpPWpGaD
Clodronate—PTGS2—Disease—EP300—urinary bladder cancer	1.16e-05	0.000162	CbGpPWpGaD
Clodronate—PTGS2—Disease—SRC—urinary bladder cancer	1.13e-05	0.000157	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PTEN—urinary bladder cancer	1.02e-05	0.000142	CbGpPWpGaD
Clodronate—PTGS2—Disease—MYC—urinary bladder cancer	1.01e-05	0.000141	CbGpPWpGaD
Clodronate—PTGS2—Disease—EGFR—urinary bladder cancer	9.87e-06	0.000138	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—EP300—urinary bladder cancer	9.7e-06	0.000136	CbGpPWpGaD
Clodronate—PTGS2—Disease—KRAS—urinary bladder cancer	9.32e-06	0.00013	CbGpPWpGaD
Clodronate—PTGS2—Disease—HRAS—urinary bladder cancer	7.93e-06	0.000111	CbGpPWpGaD
